Article info
Regular and Young Investigator Award Abstracts
Cell Therapies
177 Preclinical characterization of CYT-100 iPSC derived NK cells alone and in combination with CYT-303 NK cell engager for hepatocellular carcinoma (HCC)
Citation
177 Preclinical characterization of CYT-100 iPSC derived NK cells alone and in combination with CYT-303 NK cell engager for hepatocellular carcinoma (HCC)
Publication history
- First published November 7, 2022.
Online issue publication
April 26, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.